Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Bristol-Myers Squibb Co., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net earnings (loss) 76 1,215 1,684 (11,908) 1,762 1,934 2,077 2,267 2,025 1,608 1,429 1,283 2,372 1,552 1,061 2,029 (10,027) 1,878 (80) (766)
Depreciation and amortization, net 1,880 2,592 2,596 2,532 2,464 2,435 2,432 2,429 2,521 2,588 2,583 2,584 2,579 2,727 2,712 2,668 2,690 2,655 2,558 2,477
Deferred income taxes (791) (256) (331) (711) (1,327) (327) (1,086) (548) (624) (645) (782) (687) (1,266) (32) (163) 68 (436) 54 1,418 (53)
Stock-based compensation 120 129 125 133 127 132 137 122 119 115 116 107 133 142 157 151 171 185 213 210
Impairment charges 1,953 139 870 1 29 159 47 20 35 61 42 41 15 613 240 339 1,072 15 63 53
Divestiture gains and royalties (281) (288) (270) (280) (245) (222) (223) (194) (243) (208) (225) (387) (222) (160) (167) (135) (213) (191) (122) (173)
Acquired IPRD 30 262 132 12,949 600 80 158 75 52 30 400 333 86 270 796 5 12,259 178 54 46
Equity investment (gains) losses 205 (12) (107) (102) (53) 58 155 (165) 14 308 644 469 (465) (148) (601) (504) (245) (817) 338
Other adjustments (29) 103 (2) 22 40 269 (13) 4 44 (40) (37) 256 (53) (31) (15) (266) (1,188) (1,024) (205) 526
Receivables 143 661 (1,019) 479 (508) (247) (65) (175) (106) (674) (669) 786 (168) (260) (693) 67 (290) (159) 546 (743)
Inventories 175 (218) (225) (218) (197) (256) (16) (282) (41) (16) (13) 1 (128) 30 5 106 101 481 642 1,448
Accounts payable 517 (374) (259) 300 444 (268) (165) 187 405 (300) (19) 23 226 (139) (145) 303 132 (424) (223) 703
Rebates and discounts (405) 1,819 735 (665) (211) 1,533 492 (910) (303) 1,140 520 (930) (39) 908 215 (221)
Income taxes payable 121 (348) (1,943) 910 1,044 (412) (2,119) 884 (1,113) 60 (1,201) 831 (222) (46) (1,022) 227 (201) (2,289) (44) 229
Other 725 167 340 (608) 283 (59) 173 (1,064) 700 (46) (191) (1,073) 275 157 227 (916) 104 1,105 223 (358)
Changes in operating assets and liabilities 1,276 1,707 (2,371) 198 855 291 (1,700) (1,360) (458) 164 (1,573) (362) (56) 650 (1,413) (434) (154) (1,286) 1,144 1,279
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities 4,363 4,376 642 14,742 2,490 2,817 (190) 703 1,281 2,079 832 2,529 1,685 3,714 1,999 1,795 13,697 341 4,306 4,703
Net cash provided by operating activities 4,439 5,591 2,326 2,834 4,252 4,751 1,887 2,970 3,306 3,687 2,261 3,812 4,057 5,266 3,060 3,824 3,670 2,219 4,226 3,937
Sale and maturities of marketable debt securities 62 238 75 747 41 365 270 57 1,206 1,417 1,688 2,100 1,244 984 1,186 782 1,523 1,220 2,143 1,394
Purchase of marketable debt securities (371) (40) (84) (274) (717) (502) (355) (200) (26) (274) (1,578) (1,714) (2,070) (1,065) (1,041) (1,302) (1,024) (1,191) (1,222) (735)
Proceeds from sales of equity investments 205 55 5 148 5 62 5 63 148 2 1,521 244 409 405 115 2 12
Capital expenditures (378) (324) (262) (284) (330) (342) (259) (278) (346) (247) (272) (253) (320) (270) (210) (173) (283) (153) (131) (186)
Divestiture and other proceeds 333 255 270 241 241 247 194 227 490 221 192 402 178 188 202 180 205 200 131 205
Acquisition and other payments, net of cash acquired (47) (348) (1,373) (20,053) (581) (326) (184) (78) (116) (3,261) (467) (442) (152) (1,057) (366) (35) (12,663) (243) (110) (68)
Net cash (used in) provided by investing activities (196) (219) (1,319) (19,618) (1,346) (410) (329) (210) 1,213 (2,081) (289) 95 401 (976) 180 (143) (12,127) (165) 823 610
Proceeds from issuance of short-term debt obligations 2,987
Repayments of short-term debt obligations (269) (2,731)
Other short-term financing obligations, net (405) 95 (2,661) 3,070 (353) (10) 115 128 136 (72) 88 42 (114) 139 (123) (62) (3) (242) (48) 26
Proceeds from issuance of long-term debt 12,883 4,455 5,926 6,945
Repayments of long-term debt (2,478) (395) (2,000) (239) (1,640) (2,785) (2,877) (5,769) (500) (1,000) (4,522) (1,250) (1,500)
Repurchase of common stock (4,000) (905) (250) (2,416) (585) (5,000) (2,751) (525) (1,236) (1,775) (1,465) (81)
Dividends (1,218) (1,216) (1,217) (1,212) (1,160) (1,191) (1,197) (1,196) (1,145) (1,154) (1,150) (1,185) (1,099) (1,090) (1,099) (1,108) (1,021) (1,016) (1,021) (1,017)
Stock option proceeds and other, net (19) 16 (6) (97) 25 41 53 (92) 179 53 419 333 (3) 196 276 172 277 171 76 18
Net cash provided by (used in) financing activities (1,642) (3,852) (4,023) 14,644 967 (5,160) (2,173) (3,050) (3,246) (4,543) (3,520) (5,653) (3,967) (1,780) (3,182) (7,295) 3,483 (2,587) (993) (1,054)
Effect of exchange rates on cash, cash equivalents and restricted cash (147) 77 (22) (45) 78 (38) (8) 13 95 (66) (71) 9 (54) (28) 18 (38) 87 31 60 (67)
Increase (decrease) in cash, cash equivalents and restricted cash 2,454 1,597 (3,038) (2,185) 3,951 (857) (623) (277) 1,368 (3,003) (1,619) (1,737) 437 2,482 76 (3,652) (4,887) (502) 4,116 3,426

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Bristol-Myers Squibb Co. net cash provided by operating activities increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Bristol-Myers Squibb Co. net cash (used in) provided by investing activities increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Bristol-Myers Squibb Co. net cash provided by (used in) financing activities increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.